Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases ...

Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical ...

Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan ...

Corbus' CRB-701 shows 23% response rate in early cancer trial, but shares fall after some patients with prior Padcev ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...

Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.